Caffeic acid phenethyl ester, a promising component of propolis with a plethora of biological activities: A review on its anti-inflammatory, neuroprotective, hepatoprotective, and cardioprotective effects

Authors

  • Mai F. Tolba,

    1. Department of Pharmacology and Toxicology, Faculty of Pharmacy, Ain Shams University, Cairo, Egypt
    2. Department of Obstetrics and gynecology, The University of Texas Medical Branch, Galveston, TX, USA
    Search for more papers by this author
  • Samar S. Azab,

    1. Department of Pharmacology and Toxicology, Faculty of Pharmacy, Ain Shams University, Cairo, Egypt
    Search for more papers by this author
  • Amani E. Khalifa,

    1. Department of Pharmacology and Toxicology, Faculty of Pharmacy, Ain Shams University, Cairo, Egypt
    Search for more papers by this author
  • Sherif Z. Abdel-Rahman,

    1. Department of Obstetrics and gynecology, The University of Texas Medical Branch, Galveston, TX, USA
    Search for more papers by this author
  • Ashraf B. Abdel-Naim

    Corresponding author
    1. Department of Pharmacology and Toxicology, Faculty of Pharmacy, King Abdulaziz University, Jeddah, Saudi Arabia
    • Department of Pharmacology and Toxicology, Faculty of Pharmacy, Ain Shams University, Cairo, Egypt
    Search for more papers by this author

Address correspondence to: Ashraf B. Abdel-Naim, Department of Pharmacology and Toxicology, Faculty of Pharmacy, Ain Shams University, Cairo, 11566, Egypt. Tel: +201119998505. Fax: +20224051107. E-mail: abnaim@pharma.asu.edu.eg, abnaim@yahoo.com

Abstract

Caffeic acid phenethyl ester (CAPE) is an important active component of honey bee propolis that possesses a plethora of biological activities. Propolis is used safely in traditional medicine as a dietary supplement for its therapeutic benefits. This review highlights the recently published data about CAPE bioavailability, anti-inflammatory, neuroprotective; hepatoprotective and cardioprotective activities. CAPE showed promising efficacy both in vitro and in vivo studies in animal models with minimum adverse effects. Its effectiveness was demonstrated in multiple target organs. Despite this fact, it has not been yet investigated as a protective agent or a potential therapy in humans. Investigation of CAPE efficacy in clinical trials is strongly encouraged to elucidate its therapeutic benefit for different human diseases after performing full preclinical toxicological studies and gaining more insights into its pharmacokinetics. © 2013 IUBMB Life, 65(8):699–709, 2013

Ancillary